Browsing by author "Starling, Naureen"
Now showing items 1-17 of 17
-
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27) -
Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
Athauda, A; Watkins, D; Mohammed, K; Chau, I; Starling, N; et al. (2018-10)Background/aim Cisplatin-based radical chemoradiotherapy (CRT) is utilised in oesophagogastric (OG) cancer but the toxicity profile of cisplatin limits its use. This study aimed to evaluate the clinical characteristics and ... -
Establishing a colorectal cancer research database from routinely collected health data: the process and potential from a pilot study.
Tamm, A; Jones, HJ; Perry, W; Campbell, D; Carten, R; et al. (BMJ PUBLISHING GROUP, 2022-06-01)OBJECTIVE: Colorectal cancer is a common cause of death and morbidity. A significant amount of data are routinely collected during patient treatment, but they are not generally available for research. The National Institute ... -
Genomic loss of heterozygosity and survival in the REAL3 trial.
Smyth, EC; Cafferkey, C; Loehr, A; Waddell, T; Begum, R; et al. (2018-11-30)Background Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric cancers ... -
HER-2 directed therapies across gastrointestinal tract cancers - A new frontier.
Jones, L; Cunningham, D; Starling, N (ELSEVIER SCI LTD, 2024-09-01)Gastrointestinal (GI) cancers are common and in the metastatic setting they have a poor prognosis. The current mainstay of treatment of GI cancers is chemotherapy; however, the biomarker-directed treatment landscape is ... -
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
Tempero, M; Oh, D-Y; Tabernero, J; Reni, M; Van Cutsem, E; et al.Background First-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine. Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumor activity through tumor ... -
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities.
Young, K; Hughes, DJ; Cunningham, D; Starling, N (2018-01)Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) continues to have the worst 5-year survival of any malignancy. With 338,000 new cases diagnosed and over 300,000 deaths per year globally there is an ... -
Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer.
Davidson, M; Chau, I; Cunningham, D; Khabra, K; Iveson, T; et al. (2017-08)Aim To investigate the impact of histology on outcome in advanced oesophageal cancer treated with first-line fluoropyrimidine-based chemotherapy.Methods Individual patient data were pooled from three randomised phase III ... -
Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment.
Moorcraft, SY; Jones, T; Walker, BA; Ladas, G; Kalaitzaki, E; et al. (2017-09)This study aimed to molecularly characterise colorectal pulmonary metastases (PM) and investigate whether their molecular profiles were concordant with those of the primary tumour. Clinical data and archival formalin fixed ... -
Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.
Sclafani, F; Morano, F; Cunningham, D; Baratelli, C; Kalaitzaki, E; et al. (2017-04)Background Although treatment of localized anal cancer (AC) is well established, very little evidence is available to inform the management of advanced tumors, and the prognosis of these patients remains poor. We have ... -
Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial
Grenader, T; Waddell, T; Peckitt, C; Oates, J; Starling, N; et al. (2016-04) -
Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma.
Shah, MA; Shitara, K; Lordick, F; Bang, Y-J; Tebbutt, NC; et al. (American Association for Cancer Research (AACR), 2022-05-26)PURPOSE: To compare napabucasin (generator of reactive oxygen species) plus paclitaxel with paclitaxel only in patients with second-line advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. EXPERIMENTAL ... -
SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy.
Lau, DK; Aresu, M; Planche, T; Tran, A; Lazaro-Alcausi, R; et al. (OXFORD UNIV PRESS, 2022-11-07)INTRODUCTION: Patients with gastrointestinal (GI) cancers have an increased risk of serious complications and death from SARS-CoV-2 infection. The immunogenicity of vaccines in patients with GI cancers receiving anti-cancer ... -
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Sclafani, F; Brown, G; Cunningham, D; Rao, S; Tekkis, P; et al. (2017-06)Background The potential of chemotherapy as salvage treatment after failure of neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC) has never been explored. We conducted a single-center, retrospective ... -
Targeting deficient DNA damage repair in gastric cancer.
Young, K; Starling, N; Cunningham, D (2016-09)Introduction Over recent years our understanding of DNA damage repair has evolved leading to an expansion of therapies attempting to exploit DNA damage repair deficiencies across multiple solid tumours. Gastric cancer has ... -
The evolving immunotherapeutic landscape in advanced oesophagogastric cancer.
Flynn, M; Young, K; Cunningham, D; Starling, N (2018-01)Improvements in median overall survival in the advanced oesophagogastric (OG) setting have plateaued, underlining the need for improved therapeutic approaches in this patient population. Immunotherapeutics are inducing ... -
Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives.
Davidson, M; Starling, N (2016-01)The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain ...